Schrödinger, a New York and Portland, OR-based maker of chemical-simulation software for drug development and research, has received a $10 million equity investment from Bill Gates through Cascade Investment, Gates’s private investment and holding company. The news was reported earlier today by the Wall Street Journal. The money will be used to support R&D projects to advance the state of the art in computer-aided drug design. Schrödinger (love the name) says its software “has been used by nearly every major pharmaceutical firm worldwide as well as hundreds of smaller firms and academic and government research laboratories.” The company, founded in 1990, also has offices in San Diego, Cambridge, MA, and New York.
Author: Gregory T. Huang
Greg is a veteran journalist who has covered a wide range of science, technology, and business. As former editor in chief, he overaw daily news, features, and events across Xconomy's national network. Before joining Xconomy, he was a features editor at New Scientist magazine, where he edited and wrote articles on physics, technology, and neuroscience. Previously he was senior writer at Technology Review, where he reported on emerging technologies, R&D, and advances in computing, robotics, and applied physics. His writing has also appeared in Wired, Nature, and The Atlantic Monthly’s website. He was named a New York Times professional fellow in 2003.
Greg is the co-author of Guanxi (Simon & Schuster, 2006), about Microsoft in China and the global competition for talent and technology. Before becoming a journalist, he did research at MIT’s Artificial Intelligence Lab. He has published 20 papers in scientific journals and conferences and spoken on innovation at Adobe, Amazon, eBay, Google, HP, Microsoft, Yahoo, and other organizations. He has a Master’s and Ph.D. in electrical engineering and computer science from MIT, and a B.S. in electrical engineering from the University of Illinois, Urbana-Champaign.
View all posts by Gregory T. Huang